Background. Herpes simplex virus type 2 (HSV-2) infection is common among human immunodeficiency virus (HIV)-infected persons, and HSV reactivation increases plasma and genital HIV-1 levels. We studied HIV-1 levels during HSV suppression in coinfected persons in a placebo-controlled crossover trial.
Most HIV-infected persons are also infected with herpes simplex virus type 2 (HSV-2) [1] . The risk of HIV-1 transmission is higher in HIV-1 serodiscordant couples when the source partner has reported recent genital ulcers [2] . Plasma and genital HIV-1 levels are increased during both symptomatic and asymptomatic HSV reactivations [3] [4] [5] [6] . In vitro studies have demonstrated that HSV proteins increase HIV-1 expression [7] [8] [9] , HSV coinfection of HIV-infected cells [10] , and levels of proinflammatory cytokines during HSV reactivation, which increase HIV-1 replication [11] . These observations support the hypothesis that, by increasing HIV-1 replication, HSV may have clinical consequences for coinfected persons as well as public health consequences.
Proof-of-concept studies among HIV/HSV-coinfected persons are needed to assess whether HSV suppression consistently decreases HIV-1 levels in plasma and genital secretions. Daily suppressive therapy for HSV infection is highly effective in reducing both clinical and subclinical HSV reactivation in HIVinfected persons [12, 13] . A randomized trial in Burkina Faso recently showed that suppressive valacyclovir significantly reduced cervical and plasma HIV-1 levels [14] . This observation is consistent with a pooled analysis of 8 studies conducted in the 1990s of high-dose acyclovir in combination with mono-or dual-nucleoside antiretroviral therapy (ART), which indicated a survival benefit among HIV-infected persons who received acyclovir [15] .
To evaluate the effect of HSV-2 suppression on anogenital and plasma HIV-1 levels among men, we conducted a randomized, double-blind, placebo-controlled crossover trial of daily valacyclovir among ART-naive HIV-1/HSV-2-coinfected men who have sex with men (MSM) with CD4 cell counts Ͼ200 cells/L in Lima, Peru.
METHODS

Study Characteristics
Study design. A randomized, double-blind, placebo-controlled crossover trial of valacyclovir for HSV and HIV-1 suppression was conducted at the Asociación Civil Impacta Salud y Educación, a research organization in Lima. Eligible persons were MSM who were 18 years old, were seropositive for HIV-1 and HSV-2, had no history of antiretroviral use, and had a CD4 cell count Ͼ200 cells/L. Exclusion criteria included current or planned therapy with antiretrovirals or herpes antivirals (acyclovir, famciclovir, or valacyclovir), a history of adverse reactions to herpes antivirals, a history of seizures, a serum creatinine level Ͼ2.0 mg/dL, and hematocrit Ͻ30%.
The human experimentation guidelines of the US Department of Health and Human Services and the individual institutions were followed in the conduct of the clinical research. The institutional review boards of the University of Washington and the Asociación Civil Impacta Salud y Educación approved the protocol. Participants provided written informed consent and were compensated for travel and related expenses. Men with sexually transmitted infection (STI) syndromes at screening were treated with regimens recommended by the Peruvian Ministry of Health. At the time of the study, antiretrovirals were available in Peru in public clinics only for HIV-infected persons with CD4 cell counts Ͻ200 cells/L or with an AIDS-related condition.
Study medication. Valacyclovir (500 mg orally twice daily) and matching placebo were supplied by GlaxoSmithKline. Subjects were randomly assigned 1:1 (valacyclovir to placebo) in blocks of 10. After 8 weeks of the initial treatment, each participant crossed over to the alternative treatment for 8 weeks, separated by a 2-week washout period with daily placebo. Medication was dispensed every 2 weeks, with pill counts performed at each visit. Open-label valacyclovir (1 g orally twice daily for 3 days) was dispensed for symptomatic herpes recurrences.
Study procedures. At enrollment, participants received counseling about genital herpes and training regarding study procedures, were administered a brief questionnaire, underwent a physical exam, and had blood and rectal secretions collected. Participants came to clinic 3 times a week during each treatment period. Anoscopy was performed at each visit to collect rectal secretions, with Snostrips (for HIV-1 polymerase chain reaction [PCR]) used first followed by a Dacron swab (for HSV DNA PCR), and blood was drawn weekly. Participants also collected daily swabs of genital and perianal skin at home for HSV DNA PCR [16, 17] . At each clinic visit, participants returned their collected specimens (stored at room temperature).
Specimen Collection and Laboratory Procedures
STI tests. At screening and as clinically indicated during the study, rectal specimens were collected for Neisseria gonorrhoeae culture, and urine was collected for gonococcal and chlamydial nucleic acid amplification tests (NAAT; Aptima; Gen-Probe). Peripheral blood was collected for syphilis serological tests (rapid plasma reagin [RPR] and HSV-2 antibody [HerpeSelect-2 ELISA; Focus Technologies]). Positive HSV-2 ELISA results (by use of an index value cutoff of Ͼ3.5 to improve specificity) [18, 19] were confirmed by Western blot [20] . Gonorrhea cultures, HerpeSelect-2 ELISAs, and RPR tests were performed in Lima. Gonococcal and chlamydial NAATs and HSV Western blots were performed at the University of Washington.
Rectal specimens. Rectal mucosal specimens were obtained through an anoscope 3-4 cm above the squamocolumnar junction. For HIV-1 RNA, 3 Snostrips (Chauvin Pharmaceuticals) were saturated with rectal mucosal secretions and placed into 500 L of guanidinium solution (4 mol/L guanidinium thiocyanate, 25 mmol/L sodium citrate [pH 7], 0.5% N-lauroylsarcosine, and 0.1 mol/L 2-mercaptoethanol); for HSV DNA PCR, the swab was placed in transport medium. Specimens were frozen at Ϫ70°C within 8 h of collection. Samples were collected by 1 of 2 clinicians.
Blood specimens. Peripheral blood was collected into tubes containing EDTA (Becton Dickinson) and separated within 8 h into plasma and mononuclear cells by ficoll-hypaque gradient centrifugation. Lymphocyte subsets were determined by flow cytometry methods in Lima. Plasma aliquots were frozen at Ϫ70°C and transported to the University of Washington Retrovirology Laboratory.
HIV-1 RNA quantitation assays. HIV-1 RNA was quantified using the TaqMan real-time RNA PCR (rt-PCR) amplification assay [21] or the Amplicor HIV Monitor assay (Roche Molecular Systems). The rt-PCR assay was modified to include a second gag oligonucleotide probe with a 5'-carboxyfluorescein (FAM) reporter dye and a 3'-minor groove binder/nonfluorescent quencher (AR8: 6FAM-CTA TCC CAT TCT GC-3MGBNFQ) to enhance sensitivity. HIV-1 RNA external standards and positive and negative controls were included on each 96-well plate. To ensure that negative results were not due to loss during nucleic acid extraction or nonspecific inhibition of the PCR assay, 300 copies of an external synthetic sequence control (Gene Amplimer pAW 109 RNA [ABI catalogue N808-0037]) were added to and copurified with participant and control samples. Each PCR also contained 800 nmol/L each of the forward primer (GCC TGG GTT CCC TGT TCC) and reverse primer (CGA CGT ACC CCT GAC ATG G) and 100 nmol/L of the labeled pAW probe (VIC-CCA GGC CAA TGT CTC ACC AAG CTC TG-MGBNFQ). The laboratory was certified by the National Institute of Allergy and Infectious Diseases-sponsored Virology Quality Assurance Program to perform both assays.
HIV-1 RNA was consistently not detected in plasma from 3 of the 20 participants by the rt-PCR assay. The primer and probe binding regions of gag were sequenced from plasma aliquots from these 3 subjects. Mutations were detected in the gagbinding regions for the HXB2 and AR8 probes or the SK431 primer, likely accounting for the negative rt-PCR results. Plasma and rectal specimens from these 3 participants were subsequently tested with the Amplicor HIV Monitor assay, which yielded HIV-1 RNA; these results were included in the analysis. For the remaining men, baseline specimens were analyzed by both assays, and no significant quantitative differences were found.
For all specimens, vials were warmed, briefly mixed in a vortex mixer, and microfuged for 5 s at 12,000 g before 200 L of fluid was withdrawn for testing. Silica extraction to remove inhibitory factors was performed before PCR analysis of rectal samples. For the TaqMan assay, the lower limit of detection (LLOD) for HIV-1 quantitation in blood plasma was 120 (2.1 log 10 ) HIV-1 RNA copies/mL; for the Amplicor HIV Monitor assay, the LLOD in plasma was 400 (2.6 log 10 ) HIV-1 RNA copies/mL. Because of the small amount of fluid absorbed by the 3 rectal Snostrips (25 L) and the dilution with guanadinium, LLODs were typically 6000 (3.8 log 10 ) and 12,800 (4.1 log 10 ) HIV-1 RNA copies/mL for the TaqMan and Amplicor HIV Monitor assays, respectively. For rectal specimens, further dilutional steps were performed for specimens when repeat testing was required; thus, the LLOD exceeded these values for 9.9% of specimens.
HSV DNA Assay
DNA was extracted from 200 L of each specimen by use of the QIAamp 96 DNA Blood Kit (Qiagen) and was eluted into 100 L of AE buffer. A fluorescent probe-based rt-PCR (TaqMan; Applied Biosystems) assay was used to quantitate HSV, using 10 L of the extracted DNA for each PCR, with primers and probe sequences and PCR conditions as described eslewhere [22, 23] . To ensure that negative results were not due to nonspecific inhibition, each PCR also contained 50,000 copies of EXO DNA, 30 mmol/L of primers EXO186F and EXO315R, and 50 nmol/L of probe EXO-P, labeled at the 5' end with VIC (Perkin-Elmer Cetus) and at the 3' end with TAMRA [24] . All negative HSV PCR results required detection of EXO DNA. One positive control with 5000 copies of HSV was coprocessed with specimens. Specimens were processed in parallel with aliquots of 1ϫ PBS. Wells without DNA also were included in each PCR run.
Statistical Methods
Sample size. The primary study end point was the effect of valacyclovir on rectal mucosal HIV-1 levels. On the basis of on our previous studies among MSM [25] and assuming a 10% dropout rate, we estimated that a sample size of 20 men would provide Ͼ80% power to detect a change of 0.3 log 10 copies/mL in HIV-1 shedding in the rectum. A crossover design was used because of lower variability in HIV-1 RNA levels in plasma and rectal secretions on multiple observations from a person than between persons [25] .
Statistical analysis. HSV shedding rate was computed by dividing the days with detectable HSV in swabs collected at home or in the clinic by the total days of swab collection. HSV shedding was measured on the basis of (1) daily external anogenital swabs and (2) clinic-obtained rectal mucosal swabs. Primary analyses involved overall HSV shedding rates (either external anogenital or rectal mucosal). All analyses were done on an intent-to-treat basis, excluding the first day of study drug administration from each arm. Investigators and technologists were unaware of treatment assignments, and unblinding occurred only after all laboratory assays were completed. For undetectable HIV-1 values, the midpoint between zero and the LLOD was used; HIV-1 values were log-transformed. HSV shedding was examined as a binary variable (detected vs. not detected).
Univariate nonlinear mixed-effects models with a Poisson link were used to compute the rate ratio comparing HIV-1 detection rates in each treatment arm. The mean quantity of HIV-1 in rectal Snostrips and plasma were compared by treatment arm. Potential predictors of HIV-1 level were evaluated using linear mixed-effect models. Because HIV-1 quantity is modeled on the log 10 scale, coefficients (␤) from models are exponentiated (10 ␤ ) and compared with 1 to compute percent changes in HIV-1 quantity. Multivariate analysis with backward elimination using mixed-effects models were also performed to compare treatment arms after adjusting for CD4 cell count and HSV shedding, including interaction terms. Potential sequence effects were evaluated. Statistical analysis was performed using SAS for Windows (version 9.1).
RESULTS
Study population and protocol adherence.
Of 63 men screened, 20 met the study entry criteria and were enrolled. The median age of participants was 31 years (range, 22-44 years), and the median CD4 cell count was 406 cells/L (range,
men (40%), of whom 2 were treated for early syphilis on the basis of titers before enrollment; the other 6 were considered to have been treated adequately in the past. No rectal or urethral gonococcal or chlamydial infections were diagnosed during the study.
Nineteen men (95%) completed the 18-week study; 1 participant withdrew after 14 weeks. Participants completed a median of 46 (range, 31-48) of 48 possible clinic visits. On the basis of pill counts, the men took a median of 96.2% (range, 65.8%-100%) of study drug dispensed. Study drug was well tolerated, with no reports of serious adverse events. Four men were treated with open-label valacyclovir for herpes recurrences during the study, of which 3 occurred during placebo administration. Overall, the analysis database included 2155 days with at least 1 genital and/or perianal swab collected for HSV DNA PCR, including 904 HSV swabs from anoscopy, 844 Snostrip samples for mucosal HIV-1 detection, and 288 plasma samples. Adherence with self-collection of anogenital swabs for HSV-2 DNA PCR was high, with a median 98.6% (range, 88.4%-100%) of expected swabs collected.
HSV detection in genital and rectal swabs. HSV DNA was detected in any anogenital specimen at least once for all study participants. Overall, HSV was detected in 29% of swabs during placebo administration, compared with 4% of swabs during valacyclovir administration (P Ͻ .001) (table 2). By participant, HSV detection ranged from 11% to 68% of all swabs obtained during placebo administration and from 0% to 26% of all swabs obtained during valacyclovir administration. Among rectal swabs obtained via anoscopy, HSV was detected in 25% of swabs obtained during placebo administration and in 3% of swabs obtained during valacyclovir administration (P Ͻ .001); the ranges of rectal swabs positive for HSV by participant were 0%-96% for placebo and 0%-17% for valacyclovir. The majority of enrolled in a randomized, double-blind, placebo-controlled crossover trial of valacyclovir for the suppression of HIV-1 HSV detection was asymptomatic, with only 4 symptomatic HSV recurrences. Rectal HIV-1 levels. Overall, HIV-1 was detected in 620 (73%) of 844 rectal mucosal samples obtained from the 20 participants: 78% (333/427) of samples collected during placebo administration and in 69% (287/417) of samples collected during valacyclovir administration (P ϭ .02) (table 2). The range by participant was 0%-100% in both the placebo and valacyclovir arms, with 2 participants having 3 rectal specimens with detectable HIV, regardless of treatment arm. The mean HIV-1 levels in rectal secretions during placebo and valacyclovir administration were 5.00 (SD, 1.04) and 4.80 (SD, 1.04) log 10 copies/mL, respectively (P Ͻ .001) (table 2) .
In univariate analysis, the mean within-subject decrease in rectal HIV-1 levels during valacyclovir administration versus placebo administration was 0.16 log 10 copies/mL (95% confidence interval [CI], 0.07-0.25 log 10 copies/mL; P ϭ .0008), a 31% decrease (table 3) . Participant-level means and SDs for rectal HIV-1 levels for the treatment arms are displayed in figure  1A . No significant sequence effects between treatment arms were found (data not shown). No significant associations were noted for rectal HIV-1 shedding and CD4 cell counts (P ϭ .11) or for detection of HSV shedding by either external anogenital or rectal mucosal swabs (P ϭ .34). However, in analyzing only HSV swabs obtained by anoscope, rectal HSV detection was associated with an increase of 0.39 log 10 copies/mL in the rectal Snostrip HIV-1 level, a 150% increase (P Ͻ .0001); this association did not remain significant in a multivariate model that included treatment arm.
Plasma HIV-1 levels. HIV-1 RNA was detected in 284 (98.6%) of 288 plasma samples. Mean HIV-1 levels in plasma during placebo and valacyclovir administration were 4.50 (SD, 0.71) and 4.14 (SD, 0.71) log 10 copies/mL, respectively (P Ͻ .001) (table 2). In univariate analysis, the mean withinsubject decrease in plasma HIV-1 levels during valacyclovir administration versus placebo administration was 0.33 log 10 copies/mL (95% CI, 0.23-0.42 log 10 copies/mL; P Ͻ .0001), corresponding to a 53% decrease in the quantity of plasma HIV-1. Participant-specific means and SDs for plasma HIV-1 levels for the treatment arms are displayed in figure 1B . No significant sequence effects between treatment arms were found (data not shown). No univariate association between plasma HIV-1 level and CD4 cell counts was observed (P ϭ .18). Univariately, the detection of HSV in rectal swabs was associated with an increase of 0.27 log 10 copies/mL in HIV-1 level (P ϭ .037); this association did not remain significant in a multivariate model that included treatment arm.
In multivariate analysis, the mean within-subject decrease in plasma HIV-1 levels during daily suppressive valacyclovir was 0.33 log 10 copies/mL (P Ͻ .001). When CD4 cell count and treatment arm were included as an interaction term, there was a greater decrease in plasma HIV-1 levels for each 100-cell/mL increase in CD4 cell count for the valacyclovir arm (P ϭ .018) (figure 2).
DISCUSSION
Our findings show that antiviral drugs that effectively suppress HSV reactivation significantly reduce plasma and mucosal HIV-1 RNA levels among HIV-1/HSV-2-coinfected MSM. In this proof-of-concept crossover trial with multiple observations per participant and intensive mucosal sampling, suppressive therapy with valacyclovir (500 mg twice daily) was associated with mean reductions of 31% in rectal and 53% in plasma HIV-1 levels. Importantly, we documented that the significant reduction in HSV detection coincided with the reduction in HIV-1 level, indicating that this effect on systemic and mucosal HIV-1 
NOTE.
Estimates represent the effect of the predictors on HIV-1 plasma or rectum levels (log 10 copies/mL) in either univariate or multivariate (backwardelimination) models. HSV, herpes simplex virus; NA, not applicable (interaction terms were not tested univariately); ND, not done (indicated for terms that were not included in multivariate analysis; only 1 predictor of HSV detection was used in multivariate analysis-rectal HSV detection was used as a potential predictor in rectal HIV detection, and any HSV detection [home or clinic] was used to predict HIV detection in plasma); NS, not statistically significant when included in the multivariate model (therefore, the term was removed).
a Each 100-cell/L increase in CD4 cell count. b For HSV detection, "any" indicates detectable HSV-2 from any swab acquired in the study (home or clinic), and "rectal" indicates detectable HSV-2 DNA in a rectal swab obtained by anoscopy.
c Interaction term included to determine whether the treatment effect differed by CD4 cell count (each 100-cell/L increase).
levels was mediated through HSV suppression. Our detection of HSV in samples from the distal rectum, where mucosal secretions were sampled to quantify rectal HIV-1 shedding, further suggests a direct association between anogenital HSV reactivation and HIV-1 replication. Thus, these findings support a substantial body of research in which HSV-2 enhanced HIV-1 replication in vitro and HSV-2 reactivation increased plasma and anogenital HIV-1 load in vivo, indicating that HSV-2 may enhance HIV-1 infectiousness in coinfected persons [2, 26 -29] .
The mean decrease in plasma HIV-1 level was 0.33 log 10 copies/mL over the 2 months of HSV suppression, with a more pronounced effect among men with higher CD4 cell counts. Our findings are consistent with those of a recent trial in Burkina Faso in women, which demonstrated a mean reduction of 0.53 log 10 copies/mL in plasma HIV level with valacyclovir suppression [14] . Natural history studies indicate that such a reduction in plasma HIV-1 levels may result in clinical benefits if associated with increased CD4 cell counts and delayed HIV disease progres- sion [30, 31] . Comparable reductions in plasma HIV-1 levels ‫5.0ف(‬ log 10 copies/mL) with zidovudine monotherapy have translated into clinical benefit [32] , although the benefit was attenuated by HIV rebound due to resistance to zidovudine. However, this would not be expected with antiherpes therapy, because it acts via suppression of a cofactor in HIV-1 up-regulation rather than directly on HIV-1 transcription. Interestingly, the Burkina Faso study, during which the study drug was administered for 3 months, noted an increased effect on HIV-1 over time, suggesting that longer duration of HSV-2 suppression may achieve greater reductions in HIV-1 levels. In comparison, the present crossover trial involved 2 months of administration for each arm, and no temporal effect in HIV-1 levels was observed (data not shown). Both trials showed an increased effect with a higher CD4 cell count.
HSV replication occurs in the anogenital mucosa, and the mechanisms by which HSV reactivation increases HIV-1 levels in plasma are not well understood. Increased levels of proinflammatory genital cytokines and chemokines were observed in a cross-sectional study of HIV-1/HSV-2-coinfected African women who were shedding HSV-2, compared with those in women who were not shedding HSV-2 [33] . Among HIV/HSV-2-coinfected MSM, anorectal HSV reactivation could directly increase HIV replication in the gut lymphoid tissue, which contains large numbers of CD4 lymphocytes, dendrocytes, and macrophages. The greater reduction in plasma HIV-1 than rectal HIV-1 levels during HSV suppression is likely a reflection of biological factors and greater variability in rectal HIV-1 measurement, given the small volumes collected by Snostrips and the dilution for sufficient volume for the HIV-1 RNA assays. Complex factors likely influence HIV replication in the gutassociated lymphoid tissue, which contains more CD4 T cells than lymph nodes or the peripheral blood [34] . Further studies, including immunological and virological analyses of rectal biopsy samples, will be required to understand the pathogenesis of anorectal HSV reactivation and HIV-1 replication.
Most HSV reactivations in this cohort were asymptomatic, so HSV interventions directed at decreasing HIV-1 levels will require the use of suppressive rather than episodic treatment. Given the small proportion who shed HSV-2 during valacyclovir administration in this trial, additional studies are needed to assess the effect of greater HSV-2 suppression on HIV replication. Valacyclovir, the hydrochloride salt of the L-valyl ester of acyclovir, is rapidly and completely metabolized to acyclovir, achieves higher plasma levels than do similar doses of acyclovir, and is very safe. Studies with comparable doses of acyclovir, which is available generically at lower cost, have demonstrated comparable efficacy to valacyclovir in suppressing HSV recurrences and shedding [35, 36] . Although acyclovir-resistant strains of HSV are observed among HIV-1-and HSV-2-infected persons [37] [38] [39] , the prevalence remains low (Ͻ5%). Genital herpes lesions that are clinically refractory to acyclovir therapy because of acyclovir resistance are much less common [39, 40] , and transmission of acyclovir-resistant strains is rare [41] . The limitations of the present study include our inability to precisely quantify lower levels of rectal HIV-1 and to detect rectal mucosal abnormalities not visualized on anoscopy. Adherence was assessed by pill count and self-report, which may not perfectly measure adherence, although the high rate of HSV suppression in the valacyclovir arm indicates very high adherence to study drug. The 8-week duration of treatment may have been too short to detect the maximal effect of HSV suppression on HIV levels. A longer trial is necessary to assess whether the reduction in HIV-1 levels translates to delayed HIV disease progression and clinical benefits from delayed time to highly active ART (HAART) initiation.
In summary, this randomized, double-blind, placebo-controlled crossover trial of valacyclovir in HIV-1/HSV-2-coinfected MSM with CD4 cell counts Ͼ200 cells/L has demonstrated significant reductions in both mucosal and systemic HIV-1 levels during daily suppressive HSV therapy. Ongoing randomized trials will determine whether HSV suppression can reduce HIV-1 transmission and will address the potential for HSV suppression to delay HAART initiation. While awaiting those results regarding public health and clinical benefits of HSV suppression in HIV-1/HSV-2-coinfected persons, this study reinforces the need for HSV-2 serological testing among HIV-infected persons and the benefits of suppressive HSV therapy in those who have CD4 cell counts Ͼ200 cells/L and are not receiving ART.
